Kandagiri Spinning Mills Faces Financial Distress

Loss widened to Rs 3.25 crore from Rs 0.79 crore in previous fiscal year.
Full net worth erosion reported alongside qualified auditor opinion on going concern status.

Reader Takeaway: Severe financial distress and zero manufacturing activity pose significant risks despite new promoter-led turnaround efforts.

What just happened

Kandagiri Spinning Mills has officially ceased all manufacturing operations and transitioned into a yarn trading entity. For FY 2025-26, the company recorded a loss after tax of Rs 3.25 crore compared to a loss of Rs 0.79 crore in FY 2024-25. Revenue from operations dipped to Rs 1.82 crore. The company also sold its entire stake in associate firm SPMM Health Care Services Private Limited for Rs 2.28 crore to clear liabilities.

Why this matters

The auditor has issued a qualified opinion, citing 'material uncertainty' regarding the company's ability to operate as a going concern. With the net worth fully eroded, the business depends entirely on the turnaround plans of the new promoter, Akshayam Creations LLP, which acquired a 64.93% stake via a Share Purchase Agreement.

The backstory

The company faced significant management restructuring in August 2025. Former promoters exited, and the board was reconstituted with representatives from Akshayam Creations LLP. The shift from manufacturing to trading follows a period of persistent financial decline, with all manufacturing staff having departed the organization.

Risks to watch

Financial sustainability is the critical risk factor. The company is now solely reliant on the yarn trading market, which currently faces weak domestic and international demand. The erosion of net worth places extreme pressure on the new management to demonstrate a viable business model to stave off liquidation concerns.

What to track next

Investors should monitor the quarterly financial disclosures to see if the yarn trading business generates positive cash flows. Additionally, updates regarding further capital infusion or operational strategy shifts from the new promoter group will be essential for assessing long-term viability.